CINCINNATI, OH, June 05, 2018 (GLOBE NEWSWIRE) -- Callitas (CSE:LILY) (OTCQB:MPHMF) (FWB:T3F2), (the “Company” or “Callitas”), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, announced that its Chief Medical Cannabis Advisor Dr. Gregory Smith MD, MPH has released a new book. Aimed at patients and caregivers, “CBDPlus” explores the cannabinoid tetrahydrocannabivarin (THCV) and the benefits it can offer.
“I wrote my first book for patients, to empower them and their caregivers to use CBD oil for a variety of conditions,” said Dr. Smith. “This new book is also geared toward patients, educating them with practical advice on using THCV.”
Like CBD oil, THCV comes from hemp and has been shown to suppress appetite, blocking hunger receptors and stopping the dopamine release our bodies experience when we see or smell food. “THCV can actually stop the hormone that makes our stomachs grumble and it makes food less appetizing,” said Dr. Smith. “It has huge potential to help patients with pre-diabetes and weight issues.”
“The release of Dr. Smith’s new book is great for the entire industry, helping to position cannabis-related products in a positive light,” said James Thompson, Interim CEO and President.
Other positive news for the industry came from the U.S. Drug Enforcement Administration last week, when it clarified the ban on cannabinoids. The new directive from the DEA better clarifies the Controlled Substances Act, allowing the sale of products which “fall outside the [Controlled Substances Act] definition of marijuana (such as sterilized seeds, oil or cake made from the seeds, and mature stalks) are not controlled under the CSA.”
Additionally, a federal bill signed this week, the “right-to-try” law, gives terminally ill patients the right to seek alternative treatments, including cannabinoid-related treatments.
“The clarification from the DEA and the new right-to-try bill tremendously help the cannabinoids industry,” said Mr. Thompson. “They open up doors for cannabinoid-related products and technologies.”
About Callitas Health: Formed in early 2015, Callitas Health Inc. is an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, focused on developing innovative technologies for weight management, female sexual health and wellness, cannabis delivery technologies and other proprietary drugs. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive (www.toconceive.com), and is in the research and development and business development process for its other OTC products, CannaMint strips and orphan drug technologies. For more information visit www.callitas.com.
Notice regarding Forward Looking Statements:This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.thecse.com. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: CannaMint Strips, C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.